FILSPARI (sparsentan) — NDA/BLA submission
2026
In 2026, the Company's partner, Chugai Pharmaceutical, expects to submit a New Drug Application for sparsentan in Japan.Source filing
TVTX biotech catalysts & pipeline
TRAVERE THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
pegtibatinase — Topline data
2H 2027
Enrollment of pegtibatinase Phase 3 HARMONY Study in HCU continues; Topline data expected in 2H 2027Source filing
FILSPARI (sparsentan) — Conference presentation
2027
The SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS has completed enrollment, with data presentations anticipated in 2027.Source filing